Farallon Capital Management LLC Lowers Position in Humana Inc. (NYSE:HUM)

Farallon Capital Management LLC decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 98.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 600 shares of the insurance provider’s stock after selling 51,100 shares during the period. Farallon Capital Management LLC’s holdings in Humana were worth $224,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of HUM. CarsonAllaria Wealth Management Ltd. lifted its holdings in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the period. Hantz Financial Services Inc. purchased a new stake in Humana in the second quarter valued at about $35,000. Family Firm Inc. purchased a new stake in shares of Humana during the second quarter worth about $37,000. Hollencrest Capital Management acquired a new position in shares of Humana during the second quarter valued at about $40,000. Finally, Riverview Trust Co purchased a new position in shares of Humana in the 2nd quarter valued at approximately $44,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Robert W. Baird initiated coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 target price on the stock. Royal Bank of Canada boosted their price objective on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, September 5th. TD Cowen raised their target price on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Oppenheimer lifted their price target on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Finally, Morgan Stanley initiated coverage on Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price objective for the company. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $398.70.

Humana Stock Up 0.8 %

Shares of NYSE HUM opened at $312.74 on Tuesday. The stock has a market cap of $37.69 billion, a PE ratio of 19.47, a P/E/G ratio of 2.56 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54. The company has a 50-day moving average of $356.28 and a 200 day moving average of $345.36.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business earned $8.94 earnings per share. As a group, sell-side analysts predict that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. Humana’s payout ratio is 22.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.